DUBLIN, March 16, 2016 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/p3dnz6/global_infectious) has announced the addition of the "Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials" report to their offering.
The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.
This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2010, including financial terms where available, including over 600 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials includes:
- Trends in infectious vaccines dealmaking in the biopharma industry since 2010
- Analysis of infectious vaccines deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 600 infectious vaccines deal records
- Identify the most active infectious vaccine dealmakers since 2010
- The leading infectious vaccines deals by value since 2010
- Includes adjuvant deals and alliances since 2010
In Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific infectious therapy target
For more information visit http://www.researchandmarkets.com/research/p3dnz6/global_infectious
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets